Advent study of the farapulse™ pulsed field ablation system meets primary efficacy and safety endpoints

Noninferiority established through high treatment success, low adverse event rates findings presented at esc congress 2023 and simultaneously published in the new england journal of medicine marlborough, mass. and amsterdam , aug. 27, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced positive 12-month results from the pivotal advent clinical trial of the farapulse™ pulsed field ablation (pfa) system*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (af).
BSX Ratings Summary
BSX Quant Ranking